|1.||Ben-Eliyahu, Shamgar: 3 articles (04/2009 - 03/2005)|
|2.||Barrot, Michel: 2 articles (01/2010 - 11/2009)|
|3.||Freund-Mercier, Marie-José: 2 articles (01/2010 - 11/2009)|
|4.||Yalcin, Ipek: 2 articles (01/2010 - 11/2009)|
|5.||Melamed, Rivka: 2 articles (04/2009 - 03/2005)|
|6.||Rosenne, Ella: 2 articles (04/2009 - 03/2005)|
|7.||Ben-Eliyahu, S: 2 articles (10/2001 - 01/2000)|
|8.||Nagel, P: 1 article (09/2015)|
|9.||Bellmann, B: 1 article (09/2015)|
|10.||Roser, M: 1 article (09/2015)|
|1.||Asthma (Bronchial Asthma)
07/01/1986 - "In conclusion, aerosolized metaproterenol was well tolerated in acute childhood asthma in repeated doses, and it appeared to be associated with prolonged bronchodilation and improved outcome."
03/01/1986 - "OTC metaproterenol will aid improvement in asthma care."
08/01/1999 - "A double blind, randomized trial of two regimens of nebulized metaproterenol was conducted in patients presenting to an Emergency Department with an acute asthma exacerbation. "
06/01/1990 - "The dose-response relationship of single doses of nebulized metaproterenol sulfate 5% inhalant solution was evaluated by placebo-controlled, parallel-group study of 30 children, aged 3 to 6 years old, with stable asthma. "
02/01/1987 - "Double-blind, dose-response study of metaproterenol inhalant solution in children with acute asthma."
07/01/1995 - "One patient's pulse rate increased to more than 200 beats/min. Although effective in reversing bronchospasm, the side effects of metaproterenol when used in rapid sequence are of major concern."
09/01/1987 - "The dose-related effects of inhaled 5% metaproterenol solution in asthmatic children between the ages of six and 12 years with acute bronchospasm were evaluated. "
01/01/1988 - "In conclusion, metaproterenol is superior to cromolyn in protecting against cold-air-induced bronchospasm."
01/01/1988 - "Inhaled metaproterenol is superior to inhaled cromolyn in protecting against cold-air-induced bronchospasm."
01/01/1987 - "We used continuous noninvasive pulse oximetry to evaluate the extent and timing of oxygen saturation (SaO2) decrease in adults following metaproterenol inhalation for acute bronchospasm. "
|3.||Chronic Obstructive Pulmonary Disease (COPD)
01/29/1996 - "These results suggest that the combination of iprathropium bromide and metaproterenol inhalation solutions offers a potential therapeutic advantage to patients with symptomatic COPD over nebulized metaproterenol alone without the risk of increased side effects."
01/01/1994 - "To investigate the relationship between the emphysematous changes and bronchodilator responses in patients with chronic airflow obstruction (CAO), we studied the correlation between bronchodilator response to 10 mg inhaled metaproterenol and the extent of emphysema, using selective alveolobronchogram (SAB). "
02/01/1986 - "To evaluate comparative bronchodilator efficacy with chronic airflow obstruction (CAO), we randomly administered to ten patients week-long treatments consisting of: inhaled metaproterenol from a metered dose canister (1.30 mg six times a day) and doses of a sustained-release theophylline formulation sufficient to achieve plasma levels of 10-15 micrograms/ml; metaproterenol-placebo; theophylline-placebo; or placebo-placebo. "
04/01/1984 - "In our experience, oxygen and inhaled metaproterenol are effective treatment for exacerbations of COPD."
04/01/1991 - "Thus, ipratropium and metaproterenol similarly improved pulmonary function in COPD patients when stable and during acute exacerbations."
04/01/1979 - "In acute myocardial failure during anaesthesia or in "low cardiac ouptut" following open heart surgery no improvement in myocardial contractility is obtained by i.v.-application of potassium-canrenoate; at the present there seems no alternative to other positive inotropic agents such as calcium, glucagon, dopamine, orciprenaline and epinephrine."
04/01/1992 - "Premodulation of acute heart failure with membrane protective agents (unithiol, alpha-tocopherol, hydrocortisone), pharmacological antagonists (novodrin, alupent, isoprenaline), and the cardiotonic agent dobutamine enabled acute heart failure to be effectively treated, hemosorption to be made in early periods and cardiac events to be abolished in 80% of the patients, SCA mortality rates decreased from 11.7 to 3.2%."
|5.||Lung Diseases (Lung Disease)
01/01/1987 - "Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease."
12/15/1965 - "[On the effects of Alotec on chronic obliterative lung diseases with reference to respiratory function tests]."
01/01/1987 - "These data show that bronchospasm contributes significantly to the high pulmonary resistance in preterm infants with chronic lung disease and that metaproterenol is beneficial in the therapy of infants with chronic lung disease requiring mechanical ventilation."
01/01/1987 - "Changes in pulmonary resistance, dynamic compliance, tidal volume, and transcutaneous PO2 and PCO2 after nebulized administration of metaproterenol were evaluated in eight newborn infants (birth weight 650 to 1060 g, gestational age 25 to 28 weeks) with chronic lung disease receiving mechanical ventilation. "
01/01/2002 - "The database search used the following terms: Wheeze or asthma and Infant or Child and Short acting beta-agonist or Salbutamol (variants), Albuterol, Terbutaline (variants), Orciprenaline, Fenoterol Randomised controlled trials comparing the effect of b2-agonist against placebo in children under 2 years of age who had had two or more previous episodes of wheeze, not related to another form of chronic lung disease. "
|4.||Ipratropium (Ipratropium Bromide)
|5.||Adrenergic beta-Agonists (beta-Adrenergic Agonists)
|6.||Cromolyn Sodium (Cromoglicic Acid)
|1.||Metered Dose Inhalers (Metered Dose Inhaler)
|2.||Nebulizers and Vaporizers (Inhaler)
|3.||Artificial Respiration (Mechanical Ventilation)